JTCVS Techniques, Год журнала: 2024, Номер 26, С. 52 - 60
Опубликована: Июнь 4, 2024
A sternum-sparing approach of minimally invasive total coronary revascularization via left anterior thoracotomy demonstrated promising early outcomes in unselected patients with artery multivessel disease. Follow-up data are still missing.
Язык: Английский
European Journal of Cardio-Thoracic Surgery, Год журнала: 2023, Номер 65(2)
Опубликована: Дек. 20, 2023
A clinical guideline aims to apply all patients with a specific condition.However, there will inevitably be situations where its recommendations aren't suitable for particular patient.While healthcare professionals and others are encouraged consider these guidelines in their professional judgement, they don't override the responsibility of make decisions tailored each patient's unique circumstances.Such should aligned latest official recommendations, from relevant public health authorities, applicable rules regulations.It is important that made collaboration with, agreed upon by, patient and/or guardian or carer.
Язык: Английский
Процитировано
111
The Annals of Thoracic Surgery, Год журнала: 2024, Номер 118(1), С. 5 - 115
Опубликована: Фев. 26, 2024
Язык: Английский
Процитировано
63
Intensive Care Medicine, Год журнала: 2024, Номер 50(7), С. 1075 - 1085
Опубликована: Июль 1, 2024
After cardiac surgery, fluid bolus therapy (FBT) with 20% human albumin may facilitate less and vasopressor administration than FBT crystalloids. We aimed to determine whether, after reduces the duration of compared crystalloid FBT. conducted a multicentre, parallel-group, open-label, randomised clinical trial in six intensive care units (ICUs) involving surgery patients deemed require 240 receive up 400 mL albumin/day as FBT, followed by 4% for any subsequent on that day, or at least first 1000 mL, use thereafter. The primary outcome was cumulative therapy. Secondary outcomes included balance. Of 480 patients, 466 provided consent contributed (mean age 65 years; median EuroSCORE II 1.4). 7 (interquartile range [IQR] 0–19.6) hours 10.8 (IQR 0–22.8) crystalloids (difference − 3.8 h, 95% confidence interval [CI] 8 0.4; P = 0.08). Day one balance difference 701 CI 872 530). In when crystalloid-based associated reduced positive but did not significantly reduce
Язык: Английский
Процитировано
12
The Annals of Thoracic Surgery, Год журнала: 2023, Номер 117(2), С. 260 - 270
Опубликована: Ноя. 29, 2023
Язык: Английский
Процитировано
22
Journal of Clinical Anesthesia, Год журнала: 2024, Номер 98, С. 111580 - 111580
Опубликована: Авг. 9, 2024
Язык: Английский
Процитировано
7
Journal of Thoracic and Cardiovascular Surgery, Год журнала: 2023, Номер 167(4), С. 1316 - 1321
Опубликована: Июнь 15, 2023
Язык: Английский
Процитировано
11
EClinicalMedicine, Год журнала: 2024, Номер 68, С. 102364 - 102364
Опубликована: Янв. 8, 2024
BackgroundRBT-1 is a combination drug of stannic protoporfin (SnPP) and iron sucrose (FeS) that elicits preconditioning response through activation antioxidant, anti-inflammatory, iron-scavenging pathways, as measured by heme oxygenase-1 (HO-1), interleukin-10 (IL-10), ferritin, respectively. Our primary aim was to determine whether RBT-1 administered before surgery would safely effectively elicit in patients undergoing cardiac surgery.MethodsThis phase 2, double-blind, randomised, placebo-controlled, parallel-group, adaptive trial, conducted 19 centres across the USA, Canada, Australia, enrolled scheduled undergo non-emergent coronary artery bypass graft (CABG) and/or heart valve with cardiopulmonary bypass. Patients were randomised (1:1:1) receive either single intravenous infusion high-dose (90 mg SnPP/240 FeS), low-dose (45 or placebo within 24–48 h surgery. The outcome preoperative response, composite plasma HO-1, IL-10, ferritin. Safety assessed adverse events laboratory parameters. Prespecified criteria permitted early stopping enrichment. This trial registered ClinicalTrials.gov, NCT04564833.FindingsBetween Aug 4, 2021, Nov 9, 2022, 135 who randomly allocated study group (46 high-dose, 45 low-dose, 44 placebo), 132 (98%) included analysis 42 placebo). At interim, proceeded full enrollment without led greater than did at (geometric least squares mean [GLSM] ratio, 3.58; 95% CI, 2.91–4.41; p < 0.0001) (GLSM 2.62; 2.11–3.24; 0.0001). generally well tolerated patients. drug-related event dose-dependent photosensitivity, observed 12 (26%) 46 treated six (13%) (safety population).InterpretationRBT-1 demonstrated statistically significant cytoprotective manageable safety profile. Further research needed. A 3 planned.FundingRenibus Therapeutics, Inc.
Язык: Английский
Процитировано
4
The Annals of Thoracic Surgery, Год журнала: 2024, Номер 118(3), С. 701 - 710
Опубликована: Июнь 29, 2024
Язык: Английский
Процитировано
4
JAMA, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 11, 2024
Calcific aortic stenosis (AS) restricts the valve opening during systole due to calcification and fibrosis of either a congenital bicuspid or normal trileaflet valve. In US, AS affects 1% 2% adults older than 65 years approximately 12% 75 years. Worldwide, leads more 100 000 deaths annually.
Язык: Английский
Процитировано
4
Journal of Cardiothoracic and Vascular Anesthesia, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0